Atazanavir: Simplicity and convenience in different scenarios

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 689-700

  Pérez Elías, María Jesús ^a  

^a Hospital Ramón   (Spain)

Author keywords

Atazanavir; HIV; HIV protease inhibitor

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATENOLOL; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; DIDANOSINE; DILTIAZEM; EFAVIRENZ; ETHINYLESTRADIOL; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NORETHISTERONE; PLACEBO; PROTEINASE INHIBITOR; RAPAMYCIN; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR; ZIDOVUDINE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; JAUNDICE; LIPODYSTROPHY; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC DISORDER; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; EXPERT WITNESS; FEMALE; HALF LIFE TIME; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AREA UNDER CURVE; DRUG INTERACTIONS; EXPERT TESTIMONY; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MULTICENTER STUDIES; OLIGOPEPTIDES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34047204318     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.689     Document Type: Review

References (55)

1. HAMMER S, SAAG M, SCHECHTER M et al.: Treatment for adult HIV infection 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 296:827-843
2. BRISTOL-MEYERS SQUIBB CO.: REYATAZ® (atazanavir sulphate) capsules prescribing information. Bristol-Meyers Squibb Co., Princeton (NJ) USA (2006).
3. ROBINSON BS, RICCARDI KA, GONG YF et al.: BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. (2000) 44:2093-2099.
4. DRUSANO GL, BILELLO JA, PRESTON SL: Hollow-fiber evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. (2001) 183:1126-1129.
5. SANNE I, PILIERO P, SQUIRES K et al.: Results of a Phase II clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J. Acquir. Immune Defic. Syndr. (2003) 32:18-29.
6. TABURET AM, PIKETTY C, CHAZALLON C et al.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48(6):2091-2096.
7. O'MARA E, AGARWALA S, RANDALL D, GERALDES M, STOLTZ R, MUMMANENI V: Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) in healthy subjects [abstract 444-W]. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA (24-28 February 2002).
8. AGARWALA S, RUSSO R, MUMMANENI V, RANDALL D, GERALDES M, O'MARA E: Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [abstract H-1716]. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (27-30 September 2002).
9. MURPHY RL, SANNE I, CAHN P et al.: Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS (2003) 17:2603-2614.
10. SQUIRES K, LAZZARIN A, GATELL J et al.: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. (2004) 36:1011-1019.
11. MALAN N, KRANTZ E, DAVID N et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO (5-8 February 2006) Abstr. 107LB.
12. WOOD R, PHANUPHAK P, CAHN P et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J. Acquir. Immune Defic. Syndr. (2004) 36:684-692.
13. GATELL J, SALMON CERON D, LAZZARIN A et al.: Efficacy and safety of atazanavir (ATV) based HAART in patients switching from a stable boosted/ unboosted protease inhibitor (PI) treatment: the SWAN study. Program and abstracts of the 10th European AIDS Conference. Dublin, Ireland (17-20 November 2005) Abstr. PS1/1.
14. SWINDELLS S, DIRIENZO AG, WILKIN T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 296(7):806-814.
15. HAAS D, ZALA C, SCHRADER S et al.: Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS (2003) 17:1339-1349.
16. COHEN C, NIETO-CISNEROS L et al.; BMS AI424-043 STUDY GROUP: Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. (2005) 21(10):1683-1692.
17. JOHNSON M, GRINSZTEJN B, RODRIGUEZ C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (2006) 20(5):711-718.
18. DRONDA F, ANTELA A, PEREZ-ELIAS MJ et al.: Rescue therapy with once-daily atazanavir-based regimens for antiretroviral-experienced HIV infected patients. J. Acquir. Immune Defic. Syndr. (2006) 42(2):258-259.
19. PIKETTY C, GERARD L, CHAZALLON C: Salvage therapy with atazanavir/ ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir. Ther. (2006) 11(2):213-221.
20. PEREZ-ELÍAS MJ, GATELL J, FLORES J et al.: Effect of ritonavir-boosted atazanavir (ATV/r) in experienced HIV-infected patients regarding hepatitis B/C status. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (24-27 July 2005) Abstr. TuPe1.1C25.
21. PINEDA JA, PALACIOS R, RIVERO A et al.: Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J. Antimicrob. Chemother. (2006) 57(5):1016-1017.
22. WITEK J, MC CALLISTER S, ODES HOO L et al.: Safety of atazanavir (ATV) and atazanavir/ritonavir (ATV/r) in subjects co-infected with HIV and hepatitis B and/or C: 1100 subject-years of treatment exposure. AIDS 2006 XVI International AIDS Conference. Toronto, Canada (13-18 August 2006) Abstr. WEPE0054.
23. MORRIS A, JUETHNER S, THEROUX E: Atazanavir use in pregnancy. 3rd MS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (24-27 July 2005) Abstr. TuPe5.2P01.
24. O'MARA E, MUMMANENI V, RANDALL D et al.: Assessment of the effect of uridine diphosphate glucuronosyl transferase 1A1 genotype on indirect bilirubin elevations in healthy subjects dosed with BMS-232632. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (17-20 September 2000). Abstr. 1645.
25. PERSICO M, PERSICO E, BAKKER CT et al.: Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology (2001) 33:627-632.
26. ROTGER M, TAFFE P, BLEIBER G et al.: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. (2005) 192:1381-1386.
27. LANKISCH TO, MOEBIUS U, WEHMEIER M et al.: Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyl transferase haplotype. Hepatology (2006) 44(5):1324-1332.
28. RODRIGUEZ NOVOA S, BARREIRO P, RENDON A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C > T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. (2006) 42(2):291-295.
29. SMITH K, WEINBERG W, DEJESUS E et al.: Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/ emtricitabine (FTC) in antiretroviral-naive HIV-infected patients: 24-week results from COL103952 (ALERT). Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (27-30 September 2006) Abstr. H-1670a.
30. JEMSEK J, ARATHOON E, ARLOTTI M et al.: Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naïve HIV infected patients Clin. Infect. Dis. (2006) 42:273-280.
31. NOOR M, PARKER R, O'MARA E: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV seronegative healthy adults. AIDS (2004) 18:2137-2144.
32. PRESTON S, PILIERO P, O'MARA E et al.: Evaluation of the steady-state interaction between atazanavir (ATV) and efavirenz (EFV). Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA (24-28 February 2002) Abstr. 443.
33. DAILLY E, TRIBUT O, TATTEVIN P et al.: Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV infected patients. Eur. J. Clin. Pharmacol. (2006) 62(7):523-526.
34. O'MARA E, MUMMANENI V, BIFANO M et al.: Pilot study of the interaction between BMS-232632 and ritonavir. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (4-8 February 2002) Abstr. 740.
35. BOFFITO M, KUROWSKI M, KRUSE G et al.: Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS (2004) 18:1291-1297.
36. GUFFANTI M, DE PASCALIS C, SEMINARI E et al.: Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV positive patients. AIDS (2003) 17:2669-2672.
37. KISER JJ, LICHTENSTEIN KA, ANDERSON PL, FLETCHER CV: Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 26(4):511-514.
38. TOMILO DL, SMITH PF, OGUNDELE AB et al.: Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (2006) 26(3):341-346.
39. GUIARD-SCHMID JB, POIRIER JM, BONNARD P, MEYNARD JL: Lack of interaction between atazanavir and proton pump inhibitors in HIV infected patients treated with ritonavir-boosted atazanavir. J. Acquir. Immune 39(4):503
40. MUMMANENI V, RANDALL D, CHABUEL D, GERALDES M, O'MARA E: Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (27-30 September 2002). Abstr. H-1717.
41. FRIEDLAND G, ANDREWS L, SCHREIBMAN T et al.: Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS (2005) 19(15):1635-1641.
42. GONG YF, ROBINSON BS, ROSE RE et al.: In vitro resistance profile of the human immunodeficiency virus Type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. (2000) 44:2319-2326.
43. COLONNO R, ROSE R, MCLAREN C et al.: Identification of I50L as the signature atazanavir resistance mutation in treatment naïve HIV-1 patients receiving atazanavir-containing regimens. J. Infect. Dis. (2004) 189:1802-1810.
44. YANCHUNAS J JR, LANGLEY DR, TAO L: Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob. Agents Chemother. (2005) 49(9):3825-3832.
45. WEINHEIMER S, DISCOTTO L, FRIBORG J, YANG H, COLONNO R: Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus Type 1 genetic backbones. Antimicrob. Agents Chemother. (2005) 49(9):3816-3824.
46. SCHNELL T, SCHMIDT B, MOSCHIK G et al.: Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS (2003) 17:1258-1261.
47. COLONNO RJ, THIRY A, LIMOLI K, PARKIN N: Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus Type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. (2003) 47:1324-1333.
48. PELLEGRIN I, BREILH D, RAGNAUD JM et al.: Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther. (2006) 11(4):421-429.
49. NAEGER LK, STRUBLE KA: Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS (2006) 20(6):847-853.
50. VORA S, MARCELIN AG, GUNTHARD HF et al.: Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS (2006) 20(1):35-40.
51. COAKLEY E, CHAPPEY C, MAA J et al.: Evaluation of phenotypic clinical cutoff for atazanavir/ritonavir in patients who changed only the protease inhibitor component of HAART: a confirmatory week 2 analysis of A1424-045. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections Denver, CO (5-8 February 2006) Abstr. 634.
52. RAY JE, MARRIOTT D, BLOCH MT, MCLACHLAN AJ et al.: Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br. J. Clin. Pharmacol. (2005) 60(3):291-299.
53. BARRIOS A, RENDON AL, GALLEGO O et al.: Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin. Trials. (2004) 5(4):201-205.
54. GIANOTTI N, SEMINARI E, GUFFANTI M et al.: Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol. (2005) 28(2):119-125.
55. RICHTER A, PLADEVALL M, MANJUNATH R et al.: Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. (2005) 6(2):79-90.